TrialsgrambetaRCTs are beautiful

SUMMIT

2025

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

In 731 patients with HFpEF and obesity, tirzepatide reduced cardiovascular death or worsening heart failure compared with placebo.

Result

Efficacy: CV death or worsening HF event; KCCQ score (co-primary)HR 0.62

Below 1 favours tirzepatide, above 1 favours placebo.

Also reported: KCCQ improved by ~ 6.9 points.

Original publication
Subtopic
Obesity & HFpEF
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Packer M, et al. N Engl J Med. 2025;392(5):427-437.doi 10.1056/NEJMoa2410027

Discussion & critique

Targets the obesity phenotype of HFpEF directly. Small and event-light: the symptom (KCCQ) benefit is more robust than the hard-outcome composite.

Discussed in podcasts